Sage Therapeutics Inc (SAGE)
32.53
+0.70 (+2.20%)
USD |
NASDAQ |
May 20, 16:00
32.50
-0.03 (-0.09%)
After-Hours: 20:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 1.921B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -56.12% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 303.44 |
Price to Book Value | 1.187 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.00 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 86.51% |
News
Headline
Wire
Time (ET)
MT Newswires
05/10 12:39
MT Newswires
05/04 08:35
MT Newswires
05/04 07:59
Yahoo
05/04 06:30
MT Newswires
05/03 16:07
Yahoo
05/03 06:30
Events
DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
08/03/2022* | -- | Results | Q2 2022 | -- | -2.17 | -- | |
08/03/2022* | 08:00 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
05/03/2022 | -- | Results | Q1 2022 | -2.07 | -2.00 | -3.75% | |
05/03/2022 | 08:00 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
02/24/2022 | -- | Results | Q4 2021 | -2.12 | -2.16 | 2.00% | |
02/24/2022 | 08:00 EST | Earnings Call | Q4 2021 | -- | -- | -- | |
11/02/2021 | -- | Results | Q3 2021 | -2.21 | -1.86 | -18.78% | |
11/02/2021 | 08:00 EST | Earnings Call | Q3 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-217 program which is in Phase 3 clinical trials for post-partum depression, essential tremor, Parkinson's disease, and major depressive disorder. The company is also developing several other compounds for treatment that are in the early stage of development. |
URL | http://www.sagerx.com |
Investor Relations URL | https://investor.sagerx.com/ |
HQ State/Province | Massachusetts |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Small Cap/Value |
Next Earnings Release | Aug. 03, 2022 (est.) |
Last Earnings Release | May. 03, 2022 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Analyst Coverage
Consensus Rating
|
|
Analyst Recommendation
|
Source: S&P Global
Dividends
Dividend Per Share (TTM) | -- |
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
Yield to Market | 0.00 |
Yield to Sector | 0.00 |
Yield to Industry | 0.00 |
Last Dividend Amt. | -- |
Dividend Frequency | -- |
Last Ex-Dividend Date | -- |
Yield (TTM) | 0.00% |
Forward Yield | -- |
Payout Ratio | 0.00% |
Cash Payout Ratio | 0.00% |
Consistent Payer (5Y) | No |
Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of May 20, 2022.
Fundamentals
Revenue (TTM) | 6.307M |
Total Expenses (TTM) | 493.91M |
Net Income (TTM) | -484.18M |
Total Assets (Quarterly) | 1.706B |
Total Liabilities (Quarterly) | 87.20M |
Shareholders Equity (Quarterly) | 1.619B |
Cash from Operations (TTM) | -376.90M |
Cash from Investing (TTM) | -353.19M |
Cash from Financing (TTM) | 9.51M |
Ratings
Profile
Edit
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-217 program which is in Phase 3 clinical trials for post-partum depression, essential tremor, Parkinson's disease, and major depressive disorder. The company is also developing several other compounds for treatment that are in the early stage of development. |
URL | http://www.sagerx.com |
Investor Relations URL | https://investor.sagerx.com/ |
HQ State/Province | Massachusetts |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Small Cap/Value |
Next Earnings Release | Aug. 03, 2022 (est.) |
Last Earnings Release | May. 03, 2022 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Risk Info
Ownership
Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
Consensus Rating
|
|
Analyst Recommendation
|
Source: S&P Global
Other Resources
Whale Wisdom | 13F Filings |
Seeking Alpha | Call Transcripts |
Morningstar | Insider Trading |
Nasdaq | Institutional Ownership |
Nasdaq | Option Chain |
SEC | SEC Filings |
SAGE Tweets |